Dec162019 Anavex Life Sciences Reports Fiscal Year 2019 Financial Results And Provides Clinical Study Updates December 16, 2019
Dec102019 Anavex Life Sciences to Announce Fiscal 2019 Year End Financial Results on Monday December 16, 2019 December 10, 2019
Dec42019 Anavex Life Sciences Presents ANAVEX®2-73 (blarcamesine) Data at 12th Clinical Trials on Alzheimer’s Disease (CTAD) 2019 Conference December 4, 2019
Nov142019 Anavex Life Sciences Receives Rare Pediatric Disease Designation from FDA for ANAVEX®2-73 (blarcamesine) for the Treatment of Rett Syndrome November 14, 2019
Nov62019 Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Rett Syndrome November 6, 2019
Oct92019 Anavex Life Sciences Announces ATTENTION-AD ANAVEX®2-73 Extension Clinical Study in Early Alzheimer’s Disease October 9, 2019
Oct22019 Anavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX®2-73 for the Treatment of Alzheimer’s Disease October 2, 2019
Sep272019 Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from the U.S. Rett Syndrome Phase 2 ANAVEX®2-73 Study September 27, 2019
Sep262019 Anavex Life Sciences to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference September 26, 2019
Sep182019 Anavex Life Sciences to Present at the Ladenburg Thalmann 2019 Healthcare Conference September 18, 2019
Sep162019 Anavex Life Sciences Announces Preliminary Clinical Efficacy Data of its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patients with Rett Syndrome September 16, 2019
